ATRC News and Press, AtriCure Inc. From 09/01/20

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global Healthcare Conference being held virtually...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory r...

For Q2 , ( ATRC -6.4% ) reported worldwide revenue of $40.8M (-30.7% Y/Y), beating consensus by $4.73M, as U.S. and International revenue dropped 28.6% and 39% respectively. More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Stocks on the move, ...

Image source: The Motley Fool. AtriCure Inc   (NASDAQ: ATRC) Q2 2020 Earnings Call Jul 28, 2020 , 4:30 p.m. ET Operator Continue reading

AtriCure, Inc. (ATRC) Q2 2020 Earnings Conference Call July 28, 2020 4:30 P.M. ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President and Chief Executive Officer Andy Wade - Chief Financial Officer Conference Call Participants Suraj Kalia - Oppenheimer...

AtriCure (NASDAQ: ATRC ) : Q2 Non-GAAP EPS of -$0.38 beats by $0.16 ; GAAP EPS of -$0.20 beats by $0.37 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Worldwide revenue of $40.8 million – a decrease of 30.7% year over year U.S. revenue of $33.7 million – a decrease of 28.6% year over year International revenue of $7.1 million – a decrease of 39.0% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a lead...

Quick Take Acutus Medical ( AFIB ) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The firm designs and sells various catheter-based ablation tools to treat cardiac arrhythmias. AFIB is in early commercialization stage for its i...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020. AtriCure will host a conference call at...